Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23612201 | 0.92 | LMNA (0.39) | NPC1RAB9AKMT2ATRPV1SMN1; SMN2 | |
| SCHEMBL19510415 | 0.84 | TRPV1 (0.44) | NPC1RAB9AKMT2ATRPV1SMN1; SMN2 | |
| SCHEMBL30089471 | 0.84 | NPC1 (0.39) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL23623186 | 0.80 | SIRT2 (0.45) | — | |
| SCHEMBL5592090 | 0.79 | MGLL (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22803789 | 0.78 | ESR1 (0.49) | NPC1RAB9A | |
| SCHEMBL31548324 | 0.75 | CHRNB2 (0.36) | NPC1RAB9AKMT2ATRPV1SMN1; SMN2 | |
| SCHEMBL22777989 | 0.74 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23612059 | 0.74 | CRBN (0.33) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL23622927 | 0.73 | STING1 (0.64) | NPC1RAB9AKMT2ATRPV1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-13 | — | — | US | disclosed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-4085061-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3983383-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 859/4885RAB9A 876/4885KMT2A 3772/4885 |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 830/4885RAB9A 860/4885KMT2A 3713/4885 |
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 859/4885RAB9A 876/4885KMT2A 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.